Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies

Journal of Hepatology

Volumn 69, Issue 3, 2018, Pages 718-735

  Pimpin, Laura ^a   Cortez Pinto, Helena ^b   Negro, Francesco ^c   Corbould, Emily ^a   Lazarus, Jeffrey V ^d,e   Webber, Laura ^a   Sheron, Nick ^f  

^a UK Health Forum   (United Kingdom)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Alcohol; Epidemiology; Hepatitis; Liver disease; Obesity; Policy; Viral

Indexed keywords

ADULT; ALCOHOL CONSUMPTION; ALTERNATIVE MEDICINE; DISEASE BURDEN; EPIDEMIC; EUROPE; FEMALE; HARM REDUCTION; HEALTH CARE POLICY; HEPATITIS B; HEPATITIS C; HUMAN; INTERVENTION STUDY; LIVER CANCER; LIVER CIRRHOSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PEER REVIEW; PREVALENCE; PREVENTION STUDY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT PLANNING; TREND STUDY; VACCINATION; WORLD HEALTH ORGANIZATION; CLASSIFICATION; ORGANIZATION AND MANAGEMENT; PREVENTIVE HEALTH SERVICE; PROCEDURES;

EUROPE; HUMANS; LIVER DISEASES; PREVALENCE; PREVENTIVE HEALTH SERVICES; RISK FACTORS;

EID: 85049030723     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2018.05.011     Document Type: Review

References (155)

1. Global burden of disease project, Institute for Health Metrics and Evaluation. Global Health Data Exchange. Available from: http://ghdx.healthdata.org/.
2. European association for the study of the liver. Prospects for liver disease in the EU. Available from: http://www.easl.eu/medias/EASLimg/News/EASL_HEPAMAP_Full_Report.pdf.
3. Webber, L., Divajeva, D., Marsh, T., McPherson, K., Brown, M., Galea, G., et al. The future burden of obesity-related diseases in the 53 WHO European-Region countries and the impact of effective interventions: a modelling study. BMJ Open, 4, 2014, e004787.
4. Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384 (2014), 766–781.
5. World Health Organization Regional Office for Europe. European Detailed Mortality Database. 23 August 2016.
6. World Health Organization. European Health for All Database (HFA-DB). 23 August 2017.
7. European Liver and Intestine Transplant Association. European Liver Transplant Registry 2017. Available from: www.eltr.eu.
8. European Centre for Disease Prevention and Control. Viral Hepatitis August 2017. Available from: https://ecdc.europa.eu/en/viral-hepatitis.
9. The Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2 (2017), 161–176.
10. The Polaris Observatory Collaborators. The Global Prevalence, Cascade of Care, and Prophylaxes Coverage of Hepatitis B in 2016. Lancet Gastroenterol Hepatol (submitted).
11. European Monitoring Centre for Drugs and Drug Addition. Statistical Bulletin 2017. Available from: http://www.emcdda.europa.eu/emcdda-home-page_en.
12. Pineda E, Sanchez-Romero L, Brown M, Jaccard A, Jewell J, Galea G, et al. Feasibility of achieving the 2025 WHO global targets for body mass index: predicting obesity trends in 53 countries in the WHO European Region. Submitted to Obesity Facts, 2017.
13. International Diabetes Federation. IDF Diabetes Atlas.
14. World Health Organisation. WHO factsheet 2015 [20/12/2017]. Available from: http://www.who.int/mediacentre/factsheets/fs349/en/.
15. Burton, R., Henn, C., Lavoie, D., O'Connor, R., Perkins, C., Sweeney, K., et al. A rapid evidence review of the effectiveness and cost-effectiveness of alcohol control policies: an English perspective. Lancet 389 (2017), 1558–1580.
16. Sheron, N., Chilcott, F., Matthews, L., Challoner, B., Thomas, M., Impact of minimum price per unit of alcohol on patients with liver disease in the UK. Clin Med 14 (2014), 396–403.
17. Hart, C.L., Morrison, D.S., Batty, G.D., Mitchell, R.J., Davey, S.G., Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ, 340, 2010, c1240.
18. Younossi, Z., Henry, L., Systematic review: patient-reported outcomes in chronic hepatitis C–the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther 41 (2015), 497–520.
19. Hallager, S., Ladelund, S., Christensen, P.B., Kjaer, M., Thorup Roege, B., Gronbaek, K.E., et al. Liver-related morbidity and mortality in patients with chronic hepatitis C and cirrhosis with and without sustained virologic response. Clin Epidemiol 9 (2017), 501–516.
20. Organisation for Economic Co-operation and Development. Tackling harmful alcohol use: economics and public health policy. 2015, OECD Publishing.
21. Rehm, J., Roerecke, M., Patterns of drinking and liver cirrhosis–what do we know and where do we go?. J Hepatol 62 (2015), 1000–1001.
22. Terris, M., Epidemiology of cirrhosis of the liver: national mortality data. Am J Publ Health Nations Health 57 (1967), 2076–2088.
23. Roizen, R.M.F., Fillmore, M., Kerr, W., Overlooking Terris: a speculative reconsideration of a curious spot-blindness in the history of alcohol-control science. Contemp Drug Probl 26 (1999), 577–606.
24. Roizen, R., Kerr, W.C., Fillmore, K.M., Cirrhosis mortality and per capita consumption of distilled spirits, United States, 1949–1994: trend analysis. West J Med 171 (1999), 83–87.
25. Sheron, N., Gilmore, I., Effect of policy, economics, and the changing alcohol marketplace on alcohol related deaths in England and Wales. BMJ, 353, 2016, i1860.
26. Österberg, E., Lindeman, M., Karlsson, T., Changes in alcohol policies and public opinions in Finland 2003–2013. Drug Alcohol Rev 33 (2014), 242–248.
27. Karlsson, T., Nordic alcohol policy – in what form does it exist?. 2011, National Institute for Health and Welfare Available from: https://www.a-klinikka.fi/sites/default/files/quickuploads/file/PTS11/Karlsson_Nordic_alcohol_policy.pdf.
28. World Health Organization. Alcohol Policy Timeline Database. 2016.
29. Bloom D, Chisholm D, Llopis E, Prettner K, Stein A, Feigl A. From burden to best buys”: reducing the economic impact of non-communicable disease in low-and middle-income countries. 2011.
30. Academy of Medical Sciences. Calling time – the nation's drinking as a major health issue. 2004, Academy of Medical Sciences, London.
31. Eurocare European Alcohol Policy Alliance. Taxation 2017. Available from: www.eurocare.org/resources/policy_issues/taxation.
32. Sheron, N., Hawkey, C., Gilmore, I., Projections of alcohol deaths—a wake-up call. Lancet 377 (2011), 1297–1299.
33. Nelson, J.P., McNall, A.D., Alcohol prices, taxes, and alcohol-related harms: a critical review of natural experiments in alcohol policy for nine countries. Health Policy 120 (2016), 264–272.
34. Williams, R., Horton, R., Liver disease in the UK: a Lancet Commission. Lancet, 382, 2013, 1537.
35. Hadland, S.E., Xuan, Z., Blanchette, J.G., Heeren, T.C., Swahn, M.H., Naimi, T.S., Peer reviewed: alcohol policies and alcoholic cirrhosis mortality in the United States. Prev Chronic Dis, 12, 2015.
36. Rowe, I.A., Lessons from epidemiology: the burden of liver disease. Dig Dis 35 (2017), 304–309.
37. Sheron, N., Alcohol and liver disease in Europe – Simple measures have the potential to prevent tens of thousands of premature deaths. J Hepatol 64 (2016), 957–967.
38. Chisholm, D., Doran, C., Shibuya, K., Rehm, J., Comparative cost-effectiveness of policy instruments for reducing the global burden of alcohol, tobacco and illicit drug use. Drug Alcohol Rev 25 (2006), 553–565.
39. Wagenaar, A.C., Salois, M.J., Komro, K.A., Effects of beverage alcohol price and tax levels on drinking: a meta-analysis of 1003 estimates from 112 studies. Addiction 104 (2009), 179–190.
40. Yach, D., The origins, development, effects, and future of the WHO Framework Convention on Tobacco Control: a personal perspective. Lancet 383 (2014), 1771–1779.
41. Zhao, J., Stockwell, T., Martin, G., Macdonald, S., Vallance, K., Treno, A., et al. The relationship between minimum alcohol prices, outlet densities and alcohol-attributable deaths in British Columbia, 2002–09. Addiction 108 (2013), 1059–1069.
42. Lord Neuberger LH, Lord Mance, Lord Kerr, Lord Sumption, Lord Reed, Lord Hodge. Scotch Whisky Association and others (Appellants) v The Lord Advocate and another (Respondents) (Scotland). In: Court US, (Ed.) https://www.supremecourt.uk/cases/uksc-2017-0025.html2017.
43. Justice ECo. Judgment of the Court (Second Chamber) of 23 December 2015, Scotch Whisky Association and Others v The Lord Advocate and The Advocate General for Scotland. 2015.
44. Monteiro, M.G., Babor, T.F., Jernigan, D., Brookes, C., Alcohol marketing regulation: from research to public policy. Addiction 112 (2017), 3–6.
45. Jernigan, D., Noel, J., Landon, J., Thornton, N., Lobstein, T., Alcohol marketing and youth alcohol consumption: a systematic review of longitudinal studies published since 2008. Addiction 112 (2017), 7–20.
46. Lobstein, T., Landon, J., Thornton, N., Jernigan, D., The commercial use of digital media to market alcohol products: a narrative review. Addiction 112 (2017), 21–27.
47. Noel, J.K., Babor, T.F., Does industry self-regulation protect young people from exposure to alcohol marketing? A review of compliance and complaint studies. Addiction 112 (2017), 51–56.
48. Noel, J.K., Babor, T.F., Robaina, K., Industry self-regulation of alcohol marketing: a systematic review of content and exposure research. Addiction 112 (2017), 28–50.
49. O'donnell, A., Anderson, P., Newbury-Birch, D., Schulte, B., Schmidt, C., Reimer, J., et al. The impact of brief alcohol interventions in primary healthcare: a systematic review of reviews. Alcohol Alcohol 49:1 (2013), 66–78.
50. Elzerbi, C., Donoghue, K., Drummond, C., A comparison of the efficacy of brief interventions to reduce hazardous and harmful alcohol consumption between European and non-European countries: a systematic review and meta-analysis of randomized controlled trials. Addiction 110 (2015), 1082–1091.
51. Altamirano, J., Lopez-Pelayo, H., Michelena, J., Jones, P.D., Ortega, L., Gines, P., et al. Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: prediction and impact on long-term survival. Hepatology 66 (2017), 1842–1853.
52. Verrill, C., Markham, H., Templeton, A., Carr, N.J., Sheron, N., Alcohol-related cirrhosis–early abstinence is a key factor in prognosis, even in the most severe cases. Addiction 104 (2009), 768–774.
53. Sheron, N., Moore, M., O'Brien, W., Harris, S., Roderick, P., Feasibility of detection and intervention for alcohol-related liver disease in the community: the Alcohol and Liver Disease Detection study (ALDDeS). Br J Gen Pract 63 (2013), e698–e705.
54. Nice. Assessment and management of cirrhosis 2016.
55. Ekstedt, M., Hagstrom, H., Nasr, P., Fredrikson, M., Stal, P., Kechagias, S., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61 (2015), 1547–1554.
56. Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L., Wymer, M., Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64 (2016), 73–84.
57. Pang, Q., Zhang, J.-Y., Song, S.-D., Qu, K., Xu, X.-S., Liu, S.-S., et al. Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index. World J Gastroenterol, 21, 2015, 1650.
58. Berzigotti, A., Garcia-Tsao, G., Bosch, J., Grace, N.D., Burroughs, A.K., Morillas, R., et al. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology 54 (2011), 555–561.
59. Visscher, T.L., Viet, A., Kroesbergen, H., Seidell, J.C., Underreporting of BMI in adults and its effect on obesity prevalence estimations in the period 1998 to 2001. Obesity 14 (2006), 2054–2063.
60. Gosse, M., How accurate is self-reported BMI?. Nutr Bull 39 (2014), 105–114.
61. Huang, T.T., Drewnowski, A., Kumanyika, S.K., Glass, T.A., A systems-oriented multilevel framework for addressing obesity in the 21st century. Prev Chronic Dis, 6(3), 2009.
62. Government Office for Science. Tackling obesities: future choices – obesity system atlas. 2007.
63. World Health Organization. Population-based approaches to childhood obesity prevention. 2012.
64. Harvard T.H. Chan School of Public Health. Childhood obesity intervention cost effectiveness study (CHOICES). Available from: www.choicesproject.org/.
65. National Heart Foundation of Australia Effectiveness of food reformulation as a strategy to improve population health. Rapid Review of the Evidence. 2012.
66. National Institute for Health and Care Excellence. NICE guidance diet, nutrition and obesity. Available from: www.nice.org.uk/guidance/lifestyle-and-wellbeing/diet-nutrition-and-obesity.
67. Cairns, G., Angus, K., Hastings, G., Caraher, M., Systematic reviews of the evidence on the nature, extent and effects of food marketing to children. A retrospective summary. Appetite 62 (2013), 209–215.
68. Stuckler, D., McKee, M., Ebrahim, S., Basu, S., Manufacturing epidemics: the role of global producers in increased consumption of unhealthy commodities including processed foods, alcohol, and tobacco. PLoS Med, 9, 2012, e1001235.
69. Council on Communications and Media. Policy statement – children, adolescents, and the media. Pediatrics, 132, 2013, 958.
70. Haby, M., Vos, T., Carter, R., Moodie, M., Markwick, A., Magnus, A., et al. A new approach to assessing the health benefit from obesity interventions in children and adolescents: the assessing cost-effectiveness in obesity project. Int J Obes 30 (2006), 1463–1475.
71. World Health Organization. Scaling up action against NCDs: How much will it cost? Geneva; 2011.
72. World Health Organization. A framework for implementing the set of recommendations on the marketing of foods and non-alcoholic beverages to children. 2012.
73. World Health Organization. Global status report on noncommunicable diseases 2010. Geneva; 2011.
74. Sacks, G., Swinburn, B., Lawrence, M., Obesity Policy Action framework and analysis grids for a comprehensive policy approach to reducing obesity. Obes Rev 10 (2009), 76–86.
75. Epstein, L.H., Dearing, K.K., Roba, L.G., Finkelstein, E., The influence of taxes and subsidies on energy purchased in an experimental purchasing study. Psychol Sci 21 (2010), 406–414.
76. Epstein, L.H., Handley, E.A., Dearing, K.K., Cho, D.D., Roemmich, J.N., Paluch, R.A., et al. Purchases of food in youth: influence of price and income. Psychol Sci 17 (2006), 82–89.
77. World Health Organization. Fiscal policies for diet and prevention of noncommunicable diseases: technical meeting report, 5–6 May 2015, Geneva, Switzerland. 2016.
78. Cancer Research UK, UK Health Forum. Short and sweet: why the government should introduce a sugary drinks tax. 2016.
79. Webster, J., Reformulating food products for health: context and key issues for moving forward in Europe. 2009, The George Institute for International Health, Sydney.
80. Selmer, R.M., Kristiansen, I.S., Haglerød, A., Graff-Iversen, S., Larsen, H.K., Meyer, H.E., et al. Cost and health consequences of reducing the population intake of salt. J Epidemiol Community Health 54 (2000), 697–702.
81. Joffres, M.R., Campbell, N.R., Manns, B., Tu, K., Estimate of the benefits of a population-based reduction in dietary sodium additives on hypertension and its related health care costs in Canada. Can J Cardiol 23 (2007), 437–443.
82. Cobiac, L.J., Vos, T., Veerman, J.L., Cost-effectiveness of interventions to reduce dietary salt intake. Heart, 2010, 10.1136/hrt.2010.199240.
83. Amini, M., Djazayery, A., Majdzadeh, R., Taghdisi, M.-H., Jazayeri, S., Effect of school-based interventions to control childhood obesity: a review of reviews. Int J Prev Med, 6, 2015.
84. National Institute for Health and Care Excellence. Weight management: lifestyle services for overweight or obese adults – Public Health Guideline 2014. Available from: www.nice.org.uk/guidance/ph53.
85. World Health Organization. Interventions on diet and physical activity: what works: summary report. Geneva; 2009.
86. Johns, D.J., Hartmann-Boyce, J., Jebb, S.A., Aveyard, P., Diet or exercise interventions vs. combined behavioral weight management programs: a systematic review and meta-analysis of direct comparisons. J Acad Nutr Diet 114 (2014), 1557–1568.
87. National Institute for Health and Care Excellence. Weight management: lifestyle services for overweight or obese children and young people. Public health guideline [PH47]. 2013. Available from: https://www.nice.org.uk/guidance/ph47/chapter/9-The-evidence.
88. American Diabetes Association. Type 2. Available from: www.diabetes.org.
89. Tuomilehto, J., Lindström, J., Eriksson, J.G., Valle, T.T., Hämäläinen, H., Ilanne-Parikka, P., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344 (2001), 1343–1350.
90. Vickerman, P., Martin, N., Turner, K., Hickman, M., Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction 107 (2012), 1984–1995.
91. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 (2002), 393–403.
92. Hassan, M.M., Curley, S.A., Li, D., Kaseb, A., Davila, M., Abdalla, E.K., et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 116 (2010), 1938–1946.
93. Donadon, V., Balbi, M., Ghersetti, M., Grazioli, S., Perciaccante, A., Della Valentina, G., et al. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol, 15, 2009, 2506.
94. Donadon, V., Balbi, M., Mas, M.D., Casarin, P., Zanette, G., Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 30 (2010), 750–758.
95. Lee, M.-S., Hsu, C.-C., Wahlqvist, M.L., Tsai, H.-N., Chang, Y.-H., Huang, Y.-C., Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer, 11, 2011, 20.
96. Ferrara, A., Lewis, J.D., Quesenberry, C.P., Peng, T., Strom, B.L., Van Den Eeden, S.K., et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 34 (2011), 923–929.
97. Gandini, S., Puntoni, M., Heckman-Stoddard, B.M., Dunn, B.K., Ford, L., DeCensi, A., et al. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res 9 (2014), 867–885.
98. Stevens, R., Ali, R., Bankhead, C., Bethel, M., Cairns, B., Camisasca, R., et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia 55 (2012), 2593–2603.
99. Tsilidis, K.K., Capothanassi, D., Allen, N.E., Rizos, E.C., Lopez, D.S., van Veldhoven, K., et al. Metformin does not affect cancer risk: a cohort study in the UK Clinical Practice Research Datalink analyzed like an intention-to-treat trial. Diabetes Care 37 (2014), 2522–2532.
100. Fujita, K., Iwama, H., Miyoshi, H., Tani, J., Oura, K., Tadokoro, T., et al. Diabetes mellitus and metformin in hepatocellular carcinoma. World J Gastroenterol, 22, 2016, 6100.
101. Zhang, H., Gao, C., Fang, L., Zhao, H.-C., Yao, S.-K., Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. Scand J Gastroenterol 48 (2013), 78–87.
102. Vreman, R.A., Goodell, A.J., Rodriguez, L.A., Porco, T.C., Lustig, R.H., Kahn, J.G., Health and economic benefits of reducing sugar intake in the USA, including effects via non-alcoholic fatty liver disease: a microsimulation model. BMJ Open, 7, 2017, e013543.
103. European Centre for Disease Prevention and Control. Systematic review on hepatitis B and C prevalence in the EU/EEA. Stockholm; 2016.
104. Schweitzer, A., Horn, J., Mikolajczyk, R.T., Krause, G., Ott, J.J., Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 386 (2015), 1546–1555.
105. World Health Organization. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2017 2017. Available from: http://www.who.int/immunization/diseases/hepatitisB/HBsAg_estimates_and_methods_final_V3.pdf?ua=1.
106. Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol 3 (2018), 383–403.
107. Ott, J.J., Horn, J., Krause, G., Mikolajczyk, R.T., Time trends of chronic HBV infection over prior decades–a global analysis. J Hepatol 66 (2017), 48–54.
108. Petruzziello, A., Marigliano, S., Loquercio, G., Cozzolino, A., Cacciapuoti, C., Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol, 22, 2016, 7824.
109. The European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol 2 (2017), 325–336.
110. World Health Organization. Global Hepatitis Report 2017. Geneva; 2017.
111. Keiser, O., Giudici, F., Mullhaupt, B., Junker, C., Dufour, J.F., Moradpour, D., et al. Trends in hepatitis C-related mortality in Switzerland. J Viral Hepat 25 (2017), 152–160.
112. Mahajan, R., Xing, J., Liu, S.J., Ly, K.N., Moorman, A.C., Rupp, L., et al. Mortality among persons in care with hepatitis C virus infection: the Chronic Hepatitis Cohort Study (CHeCS), 2006–2010. Clin Infect Dis 58 (2014), 1055–1061.
113. Wedemeyer, H., Duberg, A.S., Buti, M., Rosenberg, W.M., Frankova, S., Esmat, G., et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 21 (2014), 60–89.
114. World Health Organization. Guidelines for the Prevention Care and Treatment of Persons with Chronic Hepatitis B Infection: World Health Organization; 2015.
115. World Health Organization. Draft global health sector strategies. Viral hepatitis, 2016–2021. Report by the Secretariat. Geneva; 2016.
116. Nayagam, S., Thursz, M., Sicuri, E., Conteh, L., Wiktor, S., Low-Beer, D., et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis 16 (2016), 1399–1408.
117. Poorolajal, J., Mahmoodi, M., Majdzadeh, R., Nasseri-Moghaddam, S., Haghdoost, A., Fotouhi, A., Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis. Vaccine 28 (2010), 623–631.
118. Chaiyakunapruk N et al. Hepatitis B vaccination: an updated systematic review of economic evaluations in low and middle income countries. 2017.
119. La Torre, G., Mannocci, A., Saulle, R., Colamesta, V., Meggiolaro, A., Mipatrini, D., et al. Economic evaluation of HBV vaccination: a systematic review of recent publications (2000–2013). Hum Vaccine Immunother 12 (2016), 2299–2311.
120. Drummer, H.E., Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies. Front Microbiol, 5, 2014.
121. Houghton, M., Hepatitis C: the next 25 years. Antivir Res 110 (2014), 77–78.
122. Swadling, L., Capone, S., Antrobus, R.D., Brown, A., Richardson, R., Newell, E.W., et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med, 6(261), 2014 261ra153–261ra153.
123. Stone, J., Martin, N.K., Hickman, M., Hellard, M., Scott, N., McBryde, E., et al. The potential impact of a hepatitis c vaccine for people who inject drugs: is a vaccine needed in the age of direct-acting antivirals?. PLoS One, 11, 2016, e0156213.
124. Hahné S.J., Veldhuijzen, I.K., Wiessing, L., Lim, T.-A., Salminen, M., van de Laar, M., Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis, 13, 2013, 181.
125. Brouard, C., Le, Strat Y., Larsen, C., Jauffret-Roustide, M., Lot, F., Pillonel, J., The undiagnosed chronically-infected HCV population in France. Implications for expanded testing recommendations in 2014. PLoS One, 10, 2015, e0126920.
126. Bruggmann, P., Negro, F., Bihl, F., Blach, S., Lavanchy, D., Müllhaupt, B., et al. Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland. Swiss Med Wkly, 145, 2015, w14221.
127. McGarry, L.J., Pawar, V.S., Panchmatia, H.R., Rubin, J.L., Davis, G.L., Younossi, Z.M., et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology 55 (2012), 1344–1355.
128. Rein, D.B., Smith, B.D., Wittenborn, J.S., Lesesne, S.B., Wagner, L.D., Roblin, D.W., et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in US primary care settings. Ann Intern Med 156 (2012), 263–270.
129. Chapko, M.K., Dufour, D.R., Hatia, R.I., Drobeniuc, J., Ward, J.W., Teo, C.G., Cost-effectiveness of strategies for testing current hepatitis C virus infection. Hepatology 62 (2015), 1396–1404.
130. Sehr, M.A., Joshi, K.D., Fontanesi, J.M., Wong, R.J., Bitmead, R.R., Gish, R.G., Markov modeling in hepatitis B screening and linkage to care. Theor Biol Med Modell, 14, 2017, 11.
131. Kim, D.D., Hutton, D.W., Raouf, A.A., Salama, M., Hablas, A., Seifeldin, I.A., et al. Cost-effectiveness model for hepatitis C screening and treatment: implications for Egypt and other countries with high prevalence. Glob Publ Health 10 (2015), 296–317.
132. ABPI Viral Hepatitis Initiative. Access and Uptake of Direct Acting Antiviral Medicines in the UK and selected European countries based on data from IMS Health report for ABPI VHI: Hepatitis C Treatment in Europe, AXDoF162070 2017. Available from: http://www.abpi.org.uk/our-work/library/medical-disease/Documents/Access_and_Uptake_of_Direct_Acting_Antiviral_Medicines.pdf.
133. Platt, L., Minozzi, S., Reed, J., Vickerman, P., Hagan, H., French, C., et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. 2017, The Cochrane Library.
134. Turner, K.M., Hutchinson, S., Vickerman, P., Hope, V., Craine, N., Palmateer, N., et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 106 (2011), 1978–1988.
135. Davis, S.M., Daily, S., Kristjansson, A.L., Kelley, G.A., Zullig, K., Baus, A., et al. Needle exchange programs for the prevention of hepatitis C virus infection in people who inject drugs: a systematic review with meta-analysis. Harm Reduct J, 14, 2017, 25.
136. Martin, N.K., Vickerman, P., Hickman, M., Mathematical modelling of hepatitis C treatment for injecting drug users. J Theor Biol 274 (2011), 58–66.
137. Castro-Sanchez, A., Shkedy, Z., Hens, N., Aerts, M., Geskus, R., Prins, M., et al. Estimating the force of infection for HCV in injecting drug users using interval-censored data. Epidemiol Infect 140 (2012), 1064–1074.
138. Pouget, E.R., Hagan, H., Des Jarlais, D.C., Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment. Addiction 107 (2012), 1057–1065.
139. Terrault, N.A., Dodge, J.L., Murphy, E.L., Tavis, J.E., Kiss, A., Levin, T., et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology 57 (2013), 881–889.
140. Wandeler, G., Gsponer, T., Bregenzer, A., Günthard, H.F., Clerc, O., Calmy, A., et al. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clin Infect Dis 55 (2012), 1408–1416.
141. Pufall, E., Kall, M., Shahmanesh, M., Nardone, A., Gilson, R., Delpech, V., et al. Sexualized drug use (‘chemsex’) and high-risk sexual behaviours in HIV-positive men who have sex with men. HIV Med 19 (2018), 261–270.
142. Charre, C., Cotte, L., Kramer, R., Miailhes, P., Godinot, M., Koffi, J., et al. Hepatitis C virus spread from HIV-positive to HIV-negative men who have sex with men. PLoS One, 13, 2018, e0190340.
143. Scott, N., Stoové M., Wilson, D.P., Keiser, O., El-Hayek, C., Doyle, J., et al. Eliminating hepatitis C virus as a public health threat among HIV-positive men who have sex with men: a multi-modelling approach to understand differences in sexual risk behaviour. J Int AIDS Soc, 21(1), 2018.
144. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol 69 (2018), 461–511.
145. Nemtsov, A.V., Alcohol-related human losses in Russia in the 1980s and 1990s. Addiction 97 (2002), 1413–1425.
146. Liu, B., Balkwill, A., Reeves, G., Beral, V., Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study. BMJ, 340, 2010, c912.
147. Younossi, Z., Zheng, L., Stepanova, M., Venkatesan, C., Mir, H., Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C. Aliment Pharmacol Ther 37 (2013), 703–709.
148. Mackenbach, J.P., Kulhanova, I., Bopp, M., Borrell, C., Deboosere, P., Kovacs, K., et al. Inequalities in alcohol-related mortality in 17 European countries: a retrospective analysis of mortality registers. PLoS Med, 12, 2015, e1001909.
149. Anderson, P., Chisholm, D., Fuhr, D.C., Effectiveness and cost-effectiveness of policies and programmes to reduce the harm caused by alcohol. Lancet 373 (2009), 2234–2246.
150. Regaud A, Craplet M. The ‘Loi Evin’: a French exception. Available from: http://www.ias.org.uk/What-we-do/Publication-archive/The-Globe/Issue-2-2004-amp-1-2004/The-Loi-Evin-a-French-exception.aspx.
151. Vallgårda, S., Holm, L., Jensen, J.D., The Danish tax on saturated fat: why it did not survive. Eur J Clin Nutr 69 (2015), 223–226.
152. Briggs, A.D., Mytton, O.T., Kehlbacher, A., Tiffin, R., Elhussein, A., Rayner, M., et al. Health impact assessment of the UK soft drinks industry levy: a comparative risk assessment modelling study. Lancet Publ Health 2 (2017), e15–e22.
153. Bíró A., Did the junk food tax make the Hungarians eat healthier?. Food Policy 54 (2015), 107–115.
154. Duffell, E.F., Hedrich, D., Mardh, O., Mozalevskis, A., Towards elimination of hepatitis B and C in European Union and European Economic Area countries: monitoring the World Health Organization's global health sector strategy core indicators and scaling up key interventions. Eurosurveillance, 22(9), 2017.
155. Coffin, P.O., Scott, J.D., Golden, M.R., Sullivan, S.D., Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis 54 (2012), 1259–1271.